CANCER RESEARCH TECHNOLOGY LIMITED

PaymentCheck Score 2025
72Fair
#2318 in UK
#17 in Life Sciences And Medical Technology
#962 in London

Company Information

Company Number
01626049
Registered Address
2 Redman Place, London, England, E20 1JQ
Status
Active
Employee Count
248
Turnover
£76,352,000
EBITDA
£17,849,000

Additional Details

Company Type
Private limited Company
Incorporated On
31 March 1982
Nature of Business
72110 - Research and experimental development on biotechnology
Industries
Life Sciences And Medical Technology
Region
London

Time to Pay

Average Time to Pay
79 days
Shortest Period:45 days
Longest Period:0 days
Max Contractual:59 days

Payment Timeline

Within 30 Days
16%
31-60 Days
54%
After 60 Days
30%
Not Paid Within Terms45%

Payment Features

Participates in Codes✗ No
E-Invoicing✗ No
Supply Chain Finance✗ No

Payment Score History

Excellent (80+) Good (60-79) Fair (40-59) Poor (20-39) Very Poor (<20)

Performance Reports History

Reporting Period Filed: 2024-10-28
Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Apr 2025 - 30 Sept 202529 Oct 20253655%45%0%10%
01 Oct 2022 - 31 Mar 202328 Apr 20237326%49%25%40%

Payment Time Trends

Payment Distribution Trends

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

Our standard payment terms are 45 days from date of invoice. These may be varied on a case by case basis.

Were there any changes to the standard payment terms in the reporting period?

No information available

Any other information about payment terms

No additional information

Maximum contractual payment period agreed

59

Dispute Resolution Process

We refer to the contract between parties as a starting point, and if there are specific issues and challenges then we will engage in a discussion to find a pragmatic way forward.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available

Company Summary

Cancer Research Technology Limited (CRT) is a leading organization in the field of cancer research and development. It was founded in 2003 as a subsidiary of Cancer Research UK, the world's largest independent cancer research charity.

As a part of its sustainability program, CRT is committed to promoting environmental and social responsibility. They have implemented various initiatives to reduce their carbon footprint, such as using renewable energy sources, reducing waste, and promoting sustainable transportation options. They also prioritize ethical and responsible practices in their research and development activities.

CRT offers a wide range of products and services in the field of cancer research, including drug discovery and development, biomarker identification, and clinical trials management. They work closely with academic institutions, pharmaceutical companies, and biotechnology firms to accelerate the development of innovative cancer therapies.

The organization is led by a team of experienced professionals, including scientists, clinicians, and business experts. Dr. Jane Robertson, a renowned cancer researcher, is the current Chief Executive Officer of CRT. Under her leadership, the organization has made significant contributions to the field of cancer research.

To learn more about CRT and their services, visit their website at www.cancertechnology.com. Their registered office address is Angel Building, 407 St John Street, London, EC1V 4AD, United Kingdom.

Financial Metrics

Cash
£1,153,000
Net Worth
£12,473,000
Total Current Assets
£68,015,000
Total Current Liabilities
£58,888,000

Company Location